Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers

References

• Bar J, Hod M, Merlob P. 1997. Angiotensin converting enzyme inhibitors use in the first trimester of pregnancy. International Journal of Risk and Safety in Medicine 10:23–26.
   PubMedGoogle Scholar
• Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. 2004. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Research Part A: Clinical and Molecular Teratology 70:547–549.
   PubMedGoogle Scholar
• Biswas PN, Wilton LV, Shakir SW. 2002. The safety of valsartan: results of a postmarketing surveillance study on 12,881 patients in England. Journal of Human Hypertension 16:795–803.
   PubMed Web of Science ®Google Scholar
• Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. 1999. Traditional reviews, meta-analyses and pooled analyses in epidemiology. International Journal of Epidemiology 28:1–9.
   PubMed Web of Science ®Google Scholar
• Boix E, Zapater P, Picó A, Moreno O. 2005. Teratogenicity with angiotensin II receptor antagonists in pregnancy. Journal of Endocrinological Investigation 28:1029–1031.
   PubMed Web of Science ®Google Scholar
• Bos-Thompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P . 2005. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Annals of Pharmacotherapy 39:157–161.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Nageotte MP. 2001. Fatal fetal outcome with the combined use of valsartan and atenolol. Annals of Pharmacotherapy 35:859–861.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. 2008. Drugs in pregnancy and lactation. 8th. Baltimore: Lippincott Williams and Wilkins. 614–1058.
   Google Scholar
• Burrows RF, Burrows EA. 1998. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology 38:306.
   PubMed Web of Science ®Google Scholar
• Chung NA, Lip GY, Beevers M, Beevers DG. 2001. Outcomes in women given valsartan early in pregnancy [letter]. Lancet 357:1620.
   PubMedGoogle Scholar
• Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS . 2006. Major congenital malformations after first-trimester exposure to ACE inhibitors. New England Journal of Medicine 354:2443–2451.
   PubMed Web of Science ®Google Scholar
• Correa-Villaseñor A, Cragan J, Kucik J, O'Leary L, Siffel C, Williams L. 2003. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Research Part A: Clinical and Molecular Teratology 67:617–624.
   PubMedGoogle Scholar
• Cournot MP, Vial T, Carlier P, Jonville-Bera AP, Alt M, Elefant E . 2006. Angiotensin-converting enzyme (ACE) inhibitors during first trimester of pregnancy: a French prospective collaborative study. Drug Safety 29:911–1010.
   Web of Science ®Google Scholar
• Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J . 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reproductive Toxicology [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Dickersin K, Min YI. 1993. NIH clinical trials and publication bias. Online Journal of Current Clinical Trials April:50.
   PubMedGoogle Scholar
• Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. 1991. Publication bias in clinical research. Lancet 337:867–872.
   PubMed Web of Science ®Google Scholar
• Gersak K, Cvijic M, Kornhauser CL. 2009. Angiotensin II receptor blockers in pregnancy: A report of five cases. Reproductive Toxicology 28:109–112.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L . 2004. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 27:2806–2812.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. British Medical Journal 327:557–560.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Pringle M. 2004. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet 364:423–428.
   PubMed Web of Science ®Google Scholar
• Källén BA, Otterblad OP. 2003. Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology 17:255–261.
   PubMed Web of Science ®Google Scholar
• Kalyoncu NI, Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E . 2005. Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome. Saudi Medical Journal 26:497–499.
   PubMed Web of Science ®Google Scholar
• Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GY, Beevers DG. 2011. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninetyone pregnancies. Journal of Hypertension 29:396–399.
   PubMed Web of Science ®Google Scholar
• Kreft-Jais C, Plouin PF, Tchobroutsky C, Boutroy MJ. 1988. Angiotensin-converting enzyme inhibitors in pregnancy: a survey of 22 patients given captopril and nine given enalapril. British Journal of Obstetrics and Gynaecology 95:420–422.
   PubMedGoogle Scholar
• Lain KY, Roberts JM. 2002. Contemporary concepts of the pathogenesis and management of preeclampsia. Journal of the American Medical Association 287:3183–3186.
   PubMed Web of Science ®Google Scholar
• Lennestål R, OtterbladOlausson P, Källén B. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. European Journal of Clinical Pharmacology 65:615–625.
   PubMed Web of Science ®Google Scholar
• Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. 1997. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 350:1446–1447.
   PubMed Web of Science ®Google Scholar
• Malm H, Artama M, Gissler M, Klaukka T, Merilainen J, Nylander O . 2008. First trimester use of ACE-inhibitors and risk of major malformations. Reproductive Toxicology 26:67.
   Google Scholar
• Mann RD, Mackay F, Pearce G, Freemantle S, Wilton LV. 1999. Losartan: a study of pharmacovigilance data on 14 522 patients. Journal of Human Hypertension 13:551–557.
   PubMed Web of Science ®Google Scholar
• McElhatton PR, Stephens S, Wilson G, Thomas SH. 2008. Preliminary data on exposure to angiotensin-converting enzyme inhibitors (ACEI) during pregnancy. Reproductive Toxicology 26:67.
   Google Scholar
• CDC (Centers for Disease Control and Prevention). 1997. Post-marketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy United States, Canada, and Israel. 1987–1995. Journal of the American Medical Association 277:1193–1194 and Morbidity and Mortality Weekly Report 46:240–242.
   Web of Science ®Google Scholar
• Nayar B, Singhal A, Aggarwal R, Malhotra N. 2003. Losartan induced fetal toxicity. Indian Journal of Pediatrics 70:923–924.
   PubMedGoogle Scholar
• Piper JM, Ray WA, Rosa FW. 1992. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstetrics and Gynecology 80:429–432.
   PubMed Web of Science ®Google Scholar
• Ray JG, Vermeulen MJ, Koren G. 2007. Taking ACE inhibitors during early pregnancy: is it safe? Canadian Family Physician 53:1439–1440.
   PubMed Web of Science ®Google Scholar
• Rosenthal R. 1979. The file drawer problem and tolerance for null results. Psychological Bulletin 86:638–641.
   Web of Science ®Google Scholar
• Schaefer C. 2003. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Research Part A: Clinical and Molecular Teratology 67:591–594.
   PubMedGoogle Scholar
• Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, Jacqz-Aigraina E. 2005. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. British Journal of Obstetrics and Gynaecology 112:710–712.
   Google Scholar
• Steffensen FH, Nielsen GL, Sorensen HT, Olesen C, Olsen J. 1998. Pregnancy outcome with ACE-inhibitor use in early pregnancy [letter]. Lancet 351:96.
   Web of Science ®Google Scholar
• Tabacova S, Little R, Tsong Y, Vega A, Kimme AC. 2003. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiology and Drug Safety 12:633–646.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos MP . 2010. The Newcastle—Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. Ottawa, Canada. Available at: www.ohri.ca/programs/clinical_epidemiology/oxford.htm
   Google Scholar
• Yip SK, Leung TN, Fung HY. 1998. Exposure to angiotensin-converting enzyme inhibitors during first trimester: Is it safe to fetus? Acta Obstetricia et Gynecologica Scandinavica 77:570–571.
   PubMed Web of Science ®Google Scholar